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Background: Historically bare metal stents were considered standard of care for ST-
segment elevation acute myocardial infarction (STEMI). There is limited data on
STEMI patients treated for primary angioplasty with ResoluteTM zotarolimus-eluting
stent (R-ZES) and the everolimus-eluting stent (EES).
Methods: The global RESOLUTE program enrolled STEMI patients in 4 trials:
RESOLUTE-All Comers (RAC), RESOLUTE International, RESOLUTE China, and
RESOLUTE China Registry. The multicenter R-AC trial randomized patients to R-
ZES vs. EES. STEMI was a prespeciﬁed subset analysis. Target Lesion Failure (TLF)
was deﬁned as a composite of death from cardiac causes (CD), target vessel
myocardial infarction (TV-MI), and target lesion revascularization (TLR). Stent
thrombosis (ST) was deﬁned as ARC deﬁnite/probable ST.
Results: Among 7618 patients who received R-ZES in the pooled RESOLUTE clinical
program, 854 had STEMI. Mean age was 5912 years, 81% of patients were men, 23%
had diabetes mellitus, and patients had on average 1.40.7 lesions treated. The 4-year
Kaplan-Meier incidence of TLF was 11.5%, TLR 4.8%, CD/TV-MI 8.2%, CD 5.5%,
TV-MI 2.7%, and ST 1.9%. Among the 2292 patients randomized in R-AC, 122 STEMI
patients were treated with R-ZES and 158 with EES. There were no signiﬁcant dif-
ferences at 5 years in TLF, TLR, CD, TV-MI, or ST, but there was a signiﬁcant
reduction in all cause death / TV-MI with R-ZES (5.1% vs 9.0%, p¼0.036) (Table).
Conclusions: A pooled analysis of complex STEMI patients treated with R-ZES
found R-ZES to be associated with excellent and sustained clinical outcomes. Addi-
tionally, long-term outcomes with R-ZES in STEMI patients were numerically lower
than or similar to EES; however, R-ZES had a signiﬁcant reduction in all cause death/
TV-MI as compared to EES at 5 years. Submitted on behalf of the RESOLUTE Global
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Background: A coronary self-expanding stent (Stentys S.A., Paris, France) may
overcome the drawback of difﬁcult stent sizing and avoid stent malapposition with
consequent risk of restenosis and thrombosis. This feature should be particularly
useful in case of primary percutaneous coronary interventions (PCI) in patients with
ST-elevation myocardial infarction (STEMI) or in the presence of complex coronary
anatomy like coronary ectasia (a segment of artery > 1.5 times the diameter of
adjacent segments) or bifurcations.
Methods: We tasted the efﬁcacy and safety of this stent in consecutive patients un-
dergoing PCI in our centre. The decision to use a self-expanding stent was at
discretion of the operator. The primary endpoint was the composite of the following
major adverse cardiac and cerebrovascular events (MACCE) at 12 months: death,
recurrence of myocardial infarction, target vessel revascularization (TVR) and stroke.
Results: 82 patients (mean age: 64 +/-15; men: 83%; diabetes: 22%) treated with a self-
expanding stent were enrolled. The indications for PCI were STEMI in 62%, non ST-
elevationmyocardial infarction (NSTEMI)/unstable angina in 21%, and stable angina in
17%. 40%of patients had ectatic coronary arteries (with a vessel diameter> 4.5mm) and
18% coronary bifurcated lesions. DES/BMS ratio was 56/26. Two patients (2.4%)
experienced MACCE at 12 months. In both of them a geographic miss during stent
deployment with non complete coverage of the lesion leads to TVR after few months.
Conclusions: The self-expanding stent showed a low rate of clinical events in routine
clinical practice. This stent is particularly useful in case of difﬁcult stent sizing like
STEMI, coronary ectasia or bifurcations. Self-expanding stent deployment is different
compared to the traditional stents and a learning curve is needed in order to avoid
geographic miss and achieve a good result of the procedure.B8 JACC Vol 64/11/Suppl B jTCT-26
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Background: Long-term all-comers data of the current generation everolimus-eluting
stent (Xience V, Abbott Vascular, Santa Clara, CA, USA) compared to the ﬁrst
generation paclitaxel-eluting stent (Taxus Liberté, Boston Scientiﬁc, Natick, MA,
USA; PES) in patients undergoing primary percutaneous coronary intervention (PCI)
for ST-elevating myocardial infarction (STEMI) are scarce.
Methods: The COMPARE I study was a prospective, randomized, single-center, all-
comers trial randomly allocatingpatients to receive either EESorPES (1:1). It is to date the
only randomized trial comparing EES to PES in a true all-comers population with an in-
dependent adjudicated 5-year follow-up.Weperformed a post-hoc sub-analysis in patients
treated with primary PCI. The pre-speciﬁed endpoint was major adverse cardiovascular
events (MACE) deﬁned as the composite of the safety endpoints death or myocardial
infarction (MI) and the efﬁcacy endpoint target vessel revascularization (TVR).
Results: Of the 1800 study patients, 452 patients underwent primary PCI for STEMI
(25.1%) of whom 240 were treated with EES and 212 with PES. At 5 years EES was
superior to the PES with a signiﬁcant lower incidence of the endpoints MACE and
TVR. Moreover, EES showed a trend for reduction in MI and target lesion revascu-
larization. No signiﬁcant differences were found in rates of death and deﬁnite/probable
stent thrombosis. The 5 year outcomes are tabulated.Conclusions: At 5-years EES reduced signiﬁcantly MACE in patients treated with
primary PCI for STEMI compared to PES which was mainly driven by lower rates of
TVR.
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Background: Biocompatible durable polymer coatings for drug-eluting stents (DES)
were developed to reduce the risk of stent thrombosis, which is generally increased in
the setting of acute myocardial infarction (MI). These coatings are used on novel,
ﬂexible, and highly deliverable third-generation DES, investigated in the randomized,
multicenter, all-comer DUTCH PEERS (TWENTE II) trial. Of the 1,811 eligible all-
comer patients of DUTCH PEERS, 817 (45%) were treated in the setting of acute MI.
Methods: We assessed the one-year safety and efﬁcacy of the Resolute Integrity
zotarolimus-eluting stent (ZES) (Medtronic, Santa Rosa, CA, USA) and Promus
Element everolimus-eluting stent (EES) (Boston Scientiﬁc, Natick, MA, USA) in 817
DUTCH PEERS patients who were treated for acute MI. One-year follow-up data ofSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
